Sobue Satoshi, Sekiguchi Kaneo
Department of Clinical Pharmacology, Pfizer Global R & D, Tokyo Laboratories, Pfizer Japan Inc., Shinjuku Bunka Quint Bldg., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.
Biol Pharm Bull. 2004 Sep;27(9):1428-32. doi: 10.1248/bpb.27.1428.
Tioconazole (TCZ) is an imidazole antifungal agent with broad spectrum activity. Percutaneous absorption and intracutaneous distribution of TCZ solution have been compared with TCZ cream, miconazole nitrate (MCZ) solution and bifonazole (BFZ) solution following a single topical application to abdominal skin of guinea pigs. Following application of TCZ solution, TCZ concentrations in the stratum corneum, epidermis-cutis and subcutaneous tissue were higher than those after TCZ cream application suggesting superior percutaneous penetration after TCZ solution application. The percutaneous penetration after applications of MCZ solution and BFZ solution was comparable to that of TCZ cream, but inferior to that of TCZ solution. TCZ concentrations in the stratum corneum were much higher than those in epidermis-cutis and subcutaneous tissue after applications of both TCZ formulations. The majority of applied TCZ remained in the stratum corneum at high levels for a long duration. TCZ concentrations in the stratum corneum within 24 h after applications of both TCZ formulations were more than several hundred times higher than the minimum inhibitory concentrations against most of the dermatophytes and yeasts. The effectiveness of both TCZ formulations against dermatophytoses may be due to this favorable pharmacokinetic property in the skin tissues, together with its potent antifungal activity. Percutaneous absorption of TCZ after applications of both formulations was negligible suggesting that these treatments are unlikely to produce systemic side effects.
噻康唑(TCZ)是一种具有广谱活性的咪唑类抗真菌剂。在豚鼠腹部皮肤单次局部应用后,对噻康唑溶液的经皮吸收和皮内分布与噻康唑乳膏、硝酸咪康唑(MCZ)溶液和联苯苄唑(BFZ)溶液进行了比较。应用噻康唑溶液后,角质层、表皮-真皮和皮下组织中的噻康唑浓度高于应用噻康唑乳膏后,表明应用噻康唑溶液后经皮渗透更佳。应用MCZ溶液和BFZ溶液后的经皮渗透与噻康唑乳膏相当,但低于噻康唑溶液。两种噻康唑制剂应用后,角质层中的噻康唑浓度远高于表皮-真皮和皮下组织中的浓度。大部分应用的噻康唑长时间高水平地保留在角质层中。两种噻康唑制剂应用后24小时内角质层中的噻康唑浓度比针对大多数皮肤癣菌和酵母菌的最低抑菌浓度高出数百倍。两种噻康唑制剂对皮肤癣菌病的有效性可能归因于其在皮肤组织中良好的药代动力学特性及其强大的抗真菌活性。两种制剂应用后噻康唑的经皮吸收可忽略不计,表明这些治疗不太可能产生全身性副作用。